Ramon Polo

Background

About Ramon Polo

Senior Global Regulatory Affairs and Drug Development Executive with 30+ years of international leadership experience across the US, Europe, and Asia. Proven expertise in driving major product approvals, regulatory strategy, and public health initiatives within antivirals, vaccines, infectious diseases, and rare diseases. Accomplished in leading global regulatory and development teams, securing major US government BARDA contracts, and delivering pivotal regulatory milestones including the first global submission for Ensitrelvir (Xocova) at Shionogi and EUA approvals for Janssen’s COVID-19 vaccine. A defining achievement in my career was serving as Development Leader for INCIVO (telaprevir) — the first direct-acting antiviral (DAA) for Hepatitis C virus. I led the global development strategy and cross-functional development team through to worldwide approvals in the US, EU, and other markets. INCIVO transformed the standard of care for HCV patients, more than doubled cure rates, shortened treatment durations, and marked the beginning of a therapeutic revolution toward the eventual cure of Hepatitis C. Board-level contributor and strategic advisor with a passion for building high-performing, globally integrated teams in complex, fast-paced environments. PharmD, PhD, MBA, and Harvard PMD graduate. Dual US and EU citizenship with a global perspective and readiness for new executive opportunities. Let’s connect.